New strategies for the treatment of neurotoxic side effects in CAR-T cell therapy
DOI ： ： 10.3872/j.issn.1007-385x.2019.06.001
- VernacularTitle:CAR-T细胞治疗的神经毒性副反应处理新策略
- Author:
LIU Zhaonan
1
,
2
;
HAN Weidong
3
;
JIANG Jingting
1
,
2
Author Information
1. (1. Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu, China
2. 2. Institute of Cell Therapy, Soochow University
3. Institute of Basic Medicine, General Hospital of PLA
- Publication Type:Journal Article
- Keywords:
chimeric antigen receptor modified T (CAR-T) cell;
neurotoxicity;
CAR-T cell relevant encephalopathy syndrome (CRES);
coping strategies
- From:
Chinese Journal of Cancer Biotherapy
2019;26(6):617-622
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor modified T (CAR-T) cell therapy is one of the important methods of tumor immunotherapy. The targeting, killing, proliferation and persistence of CAR-T cells are significantly enhanced than that of conventional T cells.After continuous improvement and evolution, CAR-T cell treatment has achieved excellent progress in hematological tumors and has received extensive attention. However, neurotoxicity arising from the treatment, also known as CAR-T cell relevant encephalopathy syndrome (CRES), has affected its clinical application. Exploring the pathogenesis of CRES and high-risk factors, and finding appropriate strategies is therefore critical for the prevention and treatment of CRES. Here, we take CD19-CAR-T cell treatment as example to review the symptoms and pathogenesis of CRES, discuss high-risk factors as well as coping strategies, in an effort to provide a reference for clinical treatment.
- Full text:20190601.pdf
